Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 6/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316994 | 1.00 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DCA1 | |
| SCHEMBL17368626 | 0.89 | HTR2A (0.52) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL14948494 | 0.89 | HTR2A (0.52) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL5355957 | 0.88 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DCA1 | |
| SCHEMBL18475740 | 0.86 | TRPV1 (0.49) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL24765332 | 0.85 | HTR2A (0.61) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL29966236 | 0.85 | HTR2A (0.61) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL23094585 | 0.84 | HTR2A (0.49) | PDE4APDE4BPDE4CPDE4DCA1 | |
| SCHEMBL14658624 | 0.84 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DCA1 | |
| SCHEMBL23094685 | 0.84 | POLB (0.62) | PDE4APDE4BPDE4CPDE4DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-107417501-B | Preparation method of pinaverium bromide intermediate 2-bromo-4, 5-dimethoxy benzyl bromide | 浙江师范大学 | 2020-11-13 | — | — | CN | disclosed |
| CN-107835813-B | 6, 7-dihydropyrido [2,1-a ] phthalazin-2-ones for the treatment and prevention of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-9650355-B2 | Method for preparation of justicidin a derivatives of arylnaphthalene lignan structure | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-05-16 | — | — | US | disclosed |
| US-20150336938-A1 | METHOD FOR PREPARATION OF JUSTICIDIN A DERIVATIVES OF ARYLNAPHTHALENE LIGNAN STRUCTURE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-26 | — | — | US | disclosed |
| CN-103172562-B | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | TANABE SEIYAKU CO | 2015-04-22 | — | — | CN | disclosed |
| WO-2014119892-A1 | METHOD FOR PREPARATION OF JUSTICIDIN A DERIVATIVES OF ARYLNAPHTHALENE LIGNAN STRUCTURE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-08-07 | — | — | WO | disclosed |
| CN-101374817-B | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein CETP | MITSUBISHI TANABE PHARMA CORP | 2014-07-30 | — | — | CN | disclosed |
| US-20080090831-A1 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-04-17 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319105-B2 | Methylenedioxy-fused heterocycles, especially 8,10-dioxa-4,5,6,12-tetraaza-cyclopenta[b]chrysen-13-ones; 8,10-dioxa-1,4,5,6,12-pentaaza-cyclopenta[b]chrysen-13-ones; 8,10,12-trioxa-5,6-diaza-cyclopenta[b]chrysenes; and 8,10,12-trioxa-6-aza-cyclopenta[b]chrysenes; topoisomerase inhibitors; treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| CN-1882589-A | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4A 2261/4885PDE4B 2770/4885PDE4C 2723/4885 |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | PDE4A 206/4885PDE4B 232/4885PDE4C 199/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | PDE4A 2261/4885PDE4B 2770/4885PDE4C 2723/4885 |
| US-20150336938-A1 | METHOD FOR PREPARATION OF JUSTICIDIN A DERIVATIVES OF ARYLNAPHTHALENE LIGNAN STRUCTURE | UGT1A8, NOTUM, MLN | PDE4A 3431/4885PDE4B 3603/4885PDE4C 3672/4885 |
| US-20080090831-A1 | CYTOTOXIC AGENTS | TOP1, TOP2A, TOP2B | PDE4A 656/4885PDE4B 601/4885PDE4C 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.